May 31, 2016 08:58 AM Central Daylight Time CHICAGO (BUSINESS WIRE) – TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory Tcell (Treg) therapy, announced today that it has launched the TRACT CryoBanking Program to enable individuals to donate their blood consisting of their immune cells for future treatments as Continue reading
April 29, 2016 15:07 UTC CHICAGO–(BUSINESS WIRE)– TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory T-cell (Treg) therapy, announced today that it received Food and Drug Administration (FDA) approval to initiate a Phase 2 clinical trial to investigate the efficacy and safety of its novel therapy for kidney transplant Continue reading
TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection Safety Data Presented at the American Transplant Congress Meeting Demonstrated Excellent Patient Tolerability and Supports the Start of a Phase II Trial Additional Data Analysis Showed Positive Signals Toward Efficacy CHICAGO–(BUSINESS WIRE)– TRACT Continue reading
“A kidney transplant that lasts for life. It’s the ultimate goal. But the drugs that keep a donor organ going also pose the greatest threat. Now a new approach to fighting off rejection. Chicago based TRACT Therapeutics aims to remove the need for organ transplant patients to take immunosuppressive drugs by Continue reading
